LubioScience expands partnership with Amsbio, a global leader in life science reagents with a strong footprint in the cell and gene therapy, stem cell biology, 3D and organoid cell culture, glycobiology and the biospecimen field.

The report discusses ten23’s continued progress, with multiple international certifications and SBTi target validation, demonstrating its commitment to ambitious climate targets.

SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and leader in data-driven medicine, has reached a historic milestone: more than two million patients genomic profiles analyzed on the AI-powered analytics Platform SOPHiA DDM. This achievement solidifies SOPHiA GENETICS as the gold-standard provider of actionable insights for patient care, applying AI capabilities shaped by an unmatch

Celonic Group leverages Merck’s Breez micro-bioreactor technology to optimize bioprocessing efficiency and scalability. This technology integration supports Celonic’s efforts to enhance expertise in monoclonal antibody (mAb) development and manufacturing through advanced Next-Generation Technologies. Celonic’s streamlined production, enabled by Merck’s technology, sets new standards in red

Full study results are expected in June 2025, but early results demonstrate strong potential; 60% of trial patients experienced full or partial lesion clearance.